ONMD
Bearish signal
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Financial indicators Pulls against a bullish reading. Current ratio 0.43 · operating margin -711%
- Narrative Pulls against a bullish reading. Stored narrative reading is in the bearish band
- Timing Unavailable or mixed. No stored price series
ACHAT TOTAL: 142 857 titres (~89 999,91 $ US)
- Insiders
- Yu Jeffrey
- Total bought
-
$90,000
Avg buy (VWAP, 90d window) $0.68 vs last close —
- Total sold
-
—
Avg sell (VWAP, 90d window) —
- Last activity
- 2026-09-10
- Last synced
-
2026-09-16 10:10:23
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-10 | Yu Jeffrey | Buy | 142,857 | $0.63 | $90,000 | Form 4 |
| 2026-07-30 | Kosasa Thomas | Buy | 1,449,275 | $0.69 | $1,000,000 | Form 4 |
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
Market snapshot
Signal
Bearish signalScored 2026-09-15
Despite meaningful insider cluster buying and a legitimate AI-driven catalyst (data supply agreement + drug development platform), ONMD's financial foundation is critically weak, with a liquidity score of 15, current…
The first sentence of the analysis written for ONMD on 2026-09-15 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | -37.0% | -43.7% | -12.6% | -31.2% | -10.4% | |
| Ebit Margin | -201.1% | -1552.1% | -3305.7% | -2639.5% | -251.5% | |
| Ebitda Margin | -196.3% | -1543.2% | -3302.9% | -2637.4% | -250.1% | |
| Operating Profit Margin | -711.3% | -1493.8% | -671.2% | -669.1% | -248.3% | |
| Pretax Profit Margin | -206.0% | -1575.0% | -3306.8% | -2639.5% | -269.4% | |
| Continuous Operations Profit Margin | -206.1% | -1575.3% | -3308.5% | -2641.0% | -269.4% | |
| Net Profit Margin | -206.1% | -1575.3% | -3308.5% | -2641.0% | -269.4% | |
| Bottom Line Profit Margin | -206.1% | -1575.3% | -3308.5% | -2641.0% | -269.4% | |
| Current Ratio | 0.434 | 0.188 | 0.028 | 0.015 | 0.175 | |
| Quick Ratio | 0.434 | 0.188 | 0.028 | 0.015 | 0.175 | |
| Solvency Ratio | -0.535 | -0.512 | -2.533 | -1.100 | -0.444 | |
| Cash Ratio | 0.121 | 0.009 | 0.004 | 0.010 | 0.147 | |
| Price To Earnings Ratio | -18.333 | -3.778 | -0.170 | -4.159 | -50.500 | |
| Price To Earnings Growth Ratio | 0.220 | 0.041 | -0.002 | -0.004 | -9.595 | |
| Forward Price To Earnings Growth Ratio | 0.220 | 0.041 | -0.002 | -0.004 | -9.595 | |
| Price To Earnings Diluted Ratio | -18.333 | -3.778 | -0.170 | -4.159 | -50.500 | |
| Price To Earnings Diluted Growth Ratio | 0.220 | 0.041 | -0.002 | -0.004 | -9.595 | |
| Price To Book Ratio | -16.527 | -2.394 | -0.446 | -4.805 | -26.496 | |
| Price To Sales Ratio | 36.058 | 59.384 | 5.620 | 109.851 | 138.397 | |
| Price To Free Cash Flow Ratio | -6.520 | -5.428 | -1.187 | -26.603 | -80.615 | |
| Price To Operating Cash Flow Ratio | -6.531 | -5.468 | -1.198 | -26.931 | -81.923 | |
| Debt To Assets Ratio | 0.265 | 2.351 | 11.017 | 20.359 | 5.545 | |
| Debt To Equity Ratio | -0.192 | -0.549 | -0.397 | -0.996 | -0.859 | |
| Debt To Capital Ratio | -0.238 | -1.219 | -0.658 | -226.233 | -6.078 | |
| Long Term Debt To Capital Ratio | -0.080 | 0.000 | -0.038 | -0.060 | -0.372 | |
| Financial Leverage Ratio | -0.725 | -0.234 | -0.036 | -0.049 | -0.155 | |
| Working Capital Turnover Ratio | -0.148 | -0.046 | -0.053 | -0.078 | -0.422 | |
| Operating Cash Flow Ratio | -1.555 | -0.363 | -0.373 | -0.180 | -0.388 | |
| Operating Cash Flow Sales Ratio | -5.521 | -10.860 | -4.692 | -4.079 | -1.689 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | 1.007 | 1.009 | 1.012 | 1.016 | |
| Debt Service Coverage Ratio | -6.400 | -1.114 | -7.260 | -1.210 | -0.770 | |
| Interest Coverage Ratio | -144.284 | -65.340 | -623.000 | -19.129 | -13.873 | |
| Short Term Operating Cash Flow Coverage Ratio | -21.437 | -0.797 | -1.033 | -0.190 | -0.551 | |
| Operating Cash Flow Coverage Ratio | -13.163 | -0.797 | -0.939 | -0.179 | -0.377 | |
| Capital Expenditure Coverage Ratio | -577.154 | -136.922 | -108.886 | -81.086 | -61.611 | |
| Dividend Paid And Capex Coverage Ratio | -577.154 | -136.922 | -108.886 | -81.086 | -61.611 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -18.361 | -4.714 | -0.320 | -5.019 | -56.864 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | -37.0% | ▲6.7% | ▼-10.0% |
| Ebit Margin | -201.1% | ▲1351.0% | ▲1388.9% |
| Ebitda Margin | -196.3% | ▲1346.9% | ▲1389.7% |
| Operating Profit Margin | -711.3% | ▲782.4% | ▲47.4% |
| Pretax Profit Margin | -206.0% | ▲1368.9% | ▲1393.3% |
| Continuous Operations Profit Margin | -206.1% | ▲1369.2% | ▲1394.0% |
| Net Profit Margin | -206.1% | ▲1369.2% | ▲1394.0% |
| Bottom Line Profit Margin | -206.1% | ▲1369.2% | ▲1394.0% |
| Current Ratio | 0.434 | ▲0.246 | ▲0.266 |
| Quick Ratio | 0.434 | ▲0.246 | ▲0.266 |
| Solvency Ratio | -0.535 | ▼-0.023 | ▲0.490 |
| Cash Ratio | 0.121 | ▲0.112 | ▲0.063 |
| Price To Earnings Ratio | -18.333 | ▼-14.556 | ▼-2.945 |
| Price To Earnings Growth Ratio | 0.220 | ▲0.179 | ▲2.088 |
| Forward Price To Earnings Growth Ratio | 0.220 | ▲0.179 | ▲2.088 |
| Price To Earnings Diluted Ratio | -18.333 | ▼-14.556 | ▼-2.945 |
| Price To Earnings Diluted Growth Ratio | 0.220 | ▲0.179 | ▲2.088 |
| Price To Book Ratio | -16.527 | ▼-14.133 | ▼-6.393 |
| Price To Sales Ratio | 36.058 | ▼-23.326 | ▼-33.804 |
| Price To Free Cash Flow Ratio | -6.520 | ▼-1.091 | ▲17.551 |
| Price To Operating Cash Flow Ratio | -6.531 | ▼-1.063 | ▲17.879 |
| Debt To Assets Ratio | 0.265 | ▼-2.086 | ▼-7.643 |
| Debt To Equity Ratio | -0.192 | ▲0.357 | ▲0.406 |
| Debt To Capital Ratio | -0.238 | ▲0.981 | ▲46.647 |
| Long Term Debt To Capital Ratio | -0.080 | ▼-0.080 | ▲0.030 |
| Financial Leverage Ratio | -0.726 | ▼-0.492 | ▼-0.486 |
| Working Capital Turnover Ratio | -0.148 | ▼-0.102 | ▲0.001 |
| Operating Cash Flow Ratio | -1.555 | ▼-1.192 | ▼-0.983 |
| Operating Cash Flow Sales Ratio | -5.521 | ▲5.339 | ▼-0.153 |
| Free Cash Flow Operating Cash Flow Ratio | 1.002 | ▼-0.006 | ▼-0.008 |
| Debt Service Coverage Ratio | -6.401 | ▼-5.287 | ▼-3.050 |
| Interest Coverage Ratio | -144.284 | ▼-78.943 | ▲28.842 |
| Short Term Operating Cash Flow Coverage Ratio | -21.437 | ▼-20.640 | ▼-16.636 |
| Operating Cash Flow Coverage Ratio | -13.163 | ▼-12.366 | ▼-10.072 |
| Capital Expenditure Coverage Ratio | -577.154 | ▼-440.232 | ▼-384.022 |
| Dividend Paid And Capex Coverage Ratio | -577.154 | ▼-440.232 | ▼-384.022 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -18.361 | ▼-13.647 | ▼-1.306 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $49.0M | $38.2M | $5.7M | $126.7M | $151.1M | |
| Enterprise value | $49.0M | $46.8M | $10.8M | $152.6M | $155.3M | |
| EV / Sales | 36.05x | 72.75x | 10.57x | 132.38x | 142.24x | |
| EV / Op. cash flow | -6.53x | -6.70x | -2.25x | -32.45x | -84.20x | |
| EV / Free cash flow | -6.52x | -6.65x | -2.23x | -32.06x | -82.85x | |
| EV / EBITDA | -18.36x | -4.71x | -0.32x | -5.02x | -56.86x | |
| Net debt / EBITDA | 0.01x | -0.87x | -0.15x | -0.85x | -1.54x | |
| Current ratio | 0.43x | 0.19x | 0.03x | 0.01x | 0.17x | |
| Income quality | 2.68x | 0.69x | 0.14x | 0.15x | 0.63x | |
| Graham net-net | -$0 | -$1 | -$2 | -$2 | -$0 | |
| Tax burden | 100.0% | 100.0% | 100.1% | 100.1% | 100.0% | |
| Interest burden | 102.5% | 101.5% | 100.0% | 100.0% | 107.1% | |
| Working capital | -$2.7M | -$15.6M | -$12.5M | -$25.7M | -$3.9M | |
| Invested capital | -$2.7M | -$15.5M | -$12.4M | -$25.6M | -$3.9M | |
| Return on assets | -130.2% | -271.8% | -7295.0% | -2362.4% | -333.0% | |
| Operating ROA | -328.9% | -458.5% | -782.3% | -710.4% | -447.7% | |
| Return on tangible assets | -130.2% | -271.8% | -7295.0% | -2362.4% | -333.0% | |
| Return on equity | 94.5% | 63.5% | 262.7% | 115.5% | 51.6% | |
| Return on invested capital | 416.0% | 142.5% | 88.6% | 10715.3% | 523.2% | |
| Return on capital employed | 361.5% | 62.0% | 55.4% | 31.1% | 70.1% | |
| Earnings yield | -5.7% | -26.5% | -588.7% | -24.0% | -1.9% | |
| Free cash flow yield | -15.3% | -18.4% | -84.3% | -3.8% | -1.2% | |
| Capex / Op. cash flow | -0.2% | -0.7% | -0.9% | -1.2% | -1.6% | |
| Capex / Depreciation | 20.0% | 89.5% | 157.1% | 232.0% | 206.9% | |
| Capex / Sales | 1.0% | 7.9% | 4.3% | 5.0% | 2.7% | |
| SG&A / Sales | 562.8% | 1221.9% | 456.3% | 1200.1% | 165.0% | |
| R&D / Sales | 111.5% | 228.1% | 202.3% | 138.0% | 58.9% | |
| Stock comp / Sales | 149.5% | 97.7% | 144.5% | 161.8% | 9.0% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 133d | 121d | 54d | 6d | 31d | |
| Days payables outstanding | 0d | 2517d | 1328d | 284d | 0d | |
| Operating cycle | 133d | 121d | 54d | 6d | 31d | |
| Cash conversion cycle | 133d | -2396d | -1274d | -278d | 31d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+28.3%EV / Sales ▼-50.4%EV / EBITDA ▼-289.5%EV / Op. cash flow ▲+0.169Earnings yield ▲+0.208
Profitability
Return on equity ▲+0.310Return on assets ▲+1.416Return on invested capital ▲+2.734Return on capital employed ▲+2.996Operating ROA ▲+1.295Income quality ▲+1.989Tax burden +0.000
Efficiency
Days sales outstanding ▲+12.037Days payables outstanding ▼-2516.683Operating cycle ▲+12.037Cash conversion cycle ▲+2528.720Capex / Sales ▼-0.070R&D / Sales ▼-1.167
Balance-sheet strength
Current ratio ▲+0.246Net debt / EBITDA ▲+0.871Working capital ▲+12879000.000Invested capital ▲+12827000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▼-67.6%EV / Sales ▼-74.7%EV / EBITDA ▲+67.7%EV / Op. cash flow ▲+77.670Earnings yield ▼-0.038
Profitability
Return on equity ▲+0.429Return on assets ▲+2.028Return on invested capital ▼-1.072Return on capital employed ▲+2.914Operating ROA ▲+1.187Income quality ▲+2.052Tax burden +0.000
Efficiency
Days sales outstanding ▲+102.276Days payables outstanding n/aOperating cycle ▲+102.276Cash conversion cycle ▲+102.276Capex / Sales ▼-0.018R&D / Sales ▲+0.526
Balance-sheet strength
Current ratio ▲+0.259Net debt / EBITDA ▲+1.543Working capital ▲+1187872.000Invested capital ▲+1194104.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Recent news
- 2026-08-31 OneMedNet''s iRWD Platform Enables Rapid Feasibility-to-Delivery for Leading AI-Driven Drug Development Company MINNEAPOLIS, Aug. 31, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of first-party (direct-from-source) regulatory decision-grade, AI-driven Real-World Data (RWD), today announced a new agreement to deliver de-identified, full-fidelity clinical Real-World Data to a leading AI-driven drug development company. OneMedNet''s iRWD™ Platform enabled cohort feasibility within minutes, data validation within a week, and signed contract within three weeks of initial contact, and is now delivering the data to support the customer''s development and validation of AI models designed to accelerate and improve how new therapies are discovered and developed.
- 2026-08-10 OneMedNet (NASDAQ:ONMD) Director Acquires $999,999.75 in Stock OneMedNet Corporation (NASDAQ: ONMD - Get Free Report) Director Thomas Kosasa acquired 1,449,275 shares of the stock in a transaction that occurred on Thursday, July 30th. The stock was purchased at an average price of $0.69 per share, with a total value of $999,999.75. Following the completion of the transaction, the director owned 18,538,150 shares of
- 2026-07-28 OneMedNet Secures $11.5+ Million Agreement to Supply Regulatory-Grade Real-World Data for Foundational AI Model Development MINNEAPOLIS, July 28, 2026 (GLOBE NEWSWIRE) -- OneMedNet Corporation (Nasdaq: ONMD) (“OneMedNet,” the “Company,” “we,” “us” or “our”), a leading provider of regulatory decision-grade, AI-driven Real-World Data (RWD), today announced it has entered into an agreement to supply its regulatory-grade, multi-modal imaging-centric iRWD™ platform data for use in the development and training of a foundational AI model. Under the terms of the agreement, OneMedNet will provide high-quality, de-identified, regulatory-grade healthcare data, including millions of medical imaging and associated clinical reports, with data delivery immediately.